Stock Analysis, Dividends, Split History

CIC / Capitol Investment Corp. IV financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price9.95
Volume4,700.00
Market Cap ($M)400.49
Enterprise Value ($M)400.09
Book Value ($M)5.00
Book Value / Share0.12
Price / Book80.10
NCAV ($M)-13.81
NCAV / Share-0.34
Price / NCAV-29.00
Share Statistics
Common Shares Outstanding2 40,250,000
Common Shares Outstanding 10,062,500
Scoring Models
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets405.09
Liabilities14.27
Quick Ration/a
Current Ratio2.54
Income Statement (mra) ($M)
Cash Flow Statement (mra) ($M)
Identifiers and Descriptors
Central Index Key (CIK)1709682
Industry Groups

Split History

Stock splits are used by Capitol Investment Corp. IV to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Synergy: Can It Come Back?

2018-07-17 seekingalpha
Synergy (SGYP) has been one of my of my most exasperating investments. I started small and wary last April when I wrote my first exploratory article. I doubled down several times and came to regret each one. (133-2)

Once The Trial Is Over: A Look At Synergy

2018-06-06 seekingalpha
Synergy has achieved the holy grail of an early-stage biotech company - an approved drug that is considered best in class in a relatively uncompetitive area. (308-2)